Business
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announces its participation in the following investor conferences: Mardi de la Bourse – Lyon Pôle Bourse (retail event)April 7, 2026 – CRCC Lyon, France Marc Le Bozec, Chief Executive Officer, will present the Company and meet with wealth managers, financial adv
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AOAi8WsF_WG0drr4jQwesQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announces its participation in the following investor conferences:","length":309,"tagName":"p"},{"type":"text","content":"Mardi de la Bourse – Lyon Pôle Bourse (retail event)April 7, 2026 – CRCC Lyon, France","length":86,"tagName":"p"},{"type":"text","content":"Marc Le Bozec, Chief Executive Officer, will present the Company and meet with wealth managers, financial advisors and individual investors for a Q&A session together with Thomas Gidoin, Chief Financial Officer.","length":220,"tagName":"p"},{"type":"text","content":"14th Degroof Petercam Healthcare ConferenceMay 6, 2026 – Virtual","length":70,"tagName":"p"},{"type":"text","content":"Marc Le Bozec, Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will host investor meetings.","length":117,"tagName":"p"},{"type":"text","content":"ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on LinkedIn.","length":658,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text",...